The SURMOUNT-1 trial demonstrated 20.9% mean body weight reduction at 72 weeks on tirzepatide 15mg versus 14.9% on semaglutide 2.4mg in the STEP-1 trial, suggesting the dual mechanism produces greater weight loss in head-to-head comparisons
The Findings Should Be Taken With a Grain of Salt The findings bring attention to symptoms that arent consistently reported in GLP-1 clinical trials, or symptoms that failed to meet the threshold for reporting, wrote the authors
Tell your healthcare provider if your symptoms are very bothersome or are not getting better after a few weeks
The 12mg dose became the focus for Phase 3 development
10,11,81,82 Specifically, TLR-2, TLR-4, and the myeloid differentiation primary response protein 88 (MyD88) are crucial to the inflammatory reaction of macrophages to uric acid crystals
Cell 173 , 822837 (2018)